Advancing Education on Biosimilars Act of 2021

Bill: 117-s-164
Sponsor: Sen. Hassan, Margaret Wood [D-NH]
Introduced: 2021-02-02 in the Senate
Policy area: Health
Subjects: Drug safety, medical device, and laboratory regulation
Government information and archives
Health personnel
Licensing and registrations
Medical education
Prescription drugs

Summary:
action_date: 2021-02-02
text: 

Advancing Education on Biosimilars Act of 2021

 
This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)
 
 The FDA may also maintain and operate a website to provide educational materials about biological products.

action_date: 2021-03-03
text: 

Advancing Education on Biosimilars Act of 2021

 
This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)
 
 The FDA may also maintain and operate a website to provide educational materials about biological products.

action_date: 2021-04-14
text: 

Advancing Education on Biosimilars Act of 2021

 
This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)
 
 The FDA may also maintain and operate a website to provide educational materials about biological products.

action_date: 2021-04-23
text: 

Advancing Education on Biosimilars Act of 2021

 
This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)
 
 The FDA may also maintain and operate a website to provide educational materials about biological products.


Legislative actions:
action_date: 2021-04-23
text: Became Public Law No: 117-8.
action_date: 2021-04-23
text: Became Public Law No: 117-8.
action_date: 2021-04-23
text: Signed by President.
action_date: 2021-04-23
text: Signed by President.
action_date: 2021-04-20
text: Presented to President.
action_date: 2021-04-20
text: Presented to President.
action_date: 2021-04-14
text: Motion to reconsider laid on the table Agreed to without objection.
action_date: 2021-04-14
text: On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 412 - 8 (Roll no. 101). (text: CR H1754)
action_date: 2021-04-14
text: Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 412 - 8 (Roll no. 101).(text: CR H1754)
action_date: 2021-04-14
text: Considered as unfinished business. (consideration: CR H1783-1784)
action_date: 2021-04-14
text: At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
action_date: 2021-04-14
text: DEBATE - The House proceeded with forty minutes of debate on S. 164.
action_date: 2021-04-14
text: Considered under suspension of the rules. (consideration: CR H1754-1755)
action_date: 2021-04-14
text: Mr. Pallone moved to suspend the rules and pass the bill.
action_date: 2021-03-08
text: Held at the desk.
action_date: 2021-03-08
text: Received in the House.
action_date: 2021-03-08
text: Message on Senate action sent to the House.
action_date: 2021-03-03
text: Passed Senate without amendment by Unanimous Consent. (text: CR S1021)
action_date: 2021-03-03
text: Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.(text: CR S1021)
action_date: 2021-03-03
text: Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent. (consideration: CR S1021)
action_date: 2021-03-03
text: Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.(consideration: CR S1021)
action_date: 2021-02-02
text: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
action_date: 2021-02-02
text: Introduced in Senate

Enacted as: number: 117-8